PHOENIX, April 24, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") announced that effective today, Dr. Steven James will join the Company as Vice President of Medical Affairs.
“Dr. James joins Insys with extensive research and development credentials and a proven record of accomplishments. We believe he will play a critical role in achieving our mission of improving patients’ care by leveraging our proprietary sublingual spray platform and strong capabilities in developing pharmaceutical cannabinoids. We look forward to his contributions as we further advance our pipeline of product candidates,” stated Saeed Motahari, President and Chief Executive Officer.
About Dr. Steven James
Most recently, Dr. James was the Vice President of Medical Affairs at Avanir Pharmaceuticals where he was responsible for supporting the company’s focus on neurodegenerative diseases.
Prior to Avanir, he developed or created medical affair strategies at Merck Serono and Shire Pharmaceuticals. From 2005 – 2011, as Vice President of Medical Affairs at Allergan, he managed Phase IV, medical information, education, compliance, and medical science liaison functions for the Neuroscience, Ophthalmology, Dermatology, Medical Aesthetics and Medical Device divisions. Dr. James also held leadership and clinical research positions at Eli Lilly & Company from 1995 – 1998.
Dr. James received his MD at the University of Kentucky College of Medicine, his MBA at the University of California, Irvine, CA and his Bachelor of Science at the University of Kentucky, Lexington, KY.
About Insys
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. Insys currently markets one product, SUBSYS® (fentanyl sublingual spray) but has received approval for the marketing of SYNDROS™ (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with high unmet need.
SUBSYS® and SYNDROS™ are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc.
Forward-Looking Statements
This press release contains forward-looking statements regarding (i), the anticipated commercial launch of Syndros™ and the potential products in the Company’s pipeline, (ii) the belief that the Company has the potential to benefit patients in areas of unmet medical needs and (iii) the belief that SYNDROS has distinct advantages over the current formulation of dronabinol in soft gel capsule. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. For a description of these risks facing the company, please see the risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2016 and any subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise these statements, except as may be required by law.